Monopost (Latanoprost)

Latanoprost, the active ingredient in Monopost, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of open‑angle glaucoma and ocular hypertension. GNH USA supplies Monopost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost acts on the prostaglandin pathway to reduce intra‑ocular pressure in glaucoma‑related conditions.

Open‑angle glaucoma: reduces intra‑ocular pressure to help prevent optic‑nerve damage. Ocular hypertension: lowers pressure to decrease the risk of progression to glaucoma. Secondary glaucoma: assists in controlling pressure when other mechanisms are involved.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash growth. - Darkening of iris pigmentation. - Eye irritation or foreign‑body sensation. - Blurred vision. - Dry eye sensation.

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis). - Allergic reactions such as swelling or rash. - Sudden loss of vision. - Persistent eye pain. - Corneal edema. - Unexplained visual field loss.

Before using Monopost, consider the following safety measures.

Pregnancy: consult a physician before use. Breastfeeding: exercise caution and seek medical advice. Active ocular infection: contraindicated until infection resolves. Regular IOP monitoring: schedule periodic eye‑pressure checks. Contact lens wear: avoid using lenses until the eye has adjusted. Store at room temperature: keep the bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of another prostaglandin analog: risk of additive pressure‑lowering effect. - Use with ocular anesthetics: may increase ocular irritation.

Moderate Interactions (Monitor Closely): - Co‑administration with beta‑blocker eye drops: monitor intra‑ocular pressure for additive effect. - Combination with carbonic anhydrase inhibitor eye drops: watch for excessive pressure reduction. - Systemic carbonic anhydrase inhibitors: may require IOP reassessment.